Plasma protease c1 inhibitor treatment market

Plasma Protease C1-inhibitor Treatment Market, by Drug Type (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist), by Dosage (Lyophilized and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Request Free Sample

Nov 2020
CMI4262
186 Pages
Excel & Pdf
Pharmaceutical

Summary

Hereditary angioedema (HAE) is an autosomal disorder characterized by low levels of functional C1 esterase inhibitor protein. Purified concentrate of C1 esterase inhibitors are used in HAE affected patients for the prophylactic and acute attack treatment of HAE. Several plasma protease C1-inhibitors such as Cinryze, Firazyr, Kalbitor, and Berinet have been approved for the prophylactic and acute attack treatment of hereditary angioedema.

Global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 3,289.5 million in 2020 and is expected to exhibit a CAGR of 18.2% during the forecast period (2020-2027).

Figure 1. Global Plasma Protease C1-inhibitor Treatment Market Share (%), by Drug Type, 2020

Global Plasma Protease C1-inhibitor Treatment Market – Drivers

The increasing focus of biopharmaceutical companies on development of effective plasma protease C1-inhibitor treatment drugs/therapy treating various health conditions such as HAE, diabetic macular edema (DME), and others, is expected to drive growth of the plasma protease C1-inhibitor treatment market. Several kallikrein inhibitor therapies are currently in preclinical and clinical development stages. For instance, in September 2019, Oxurion released positive topline data from a phase 1 study of THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME). Moreover, in December 2019, KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced results of the Phase 2 clinical trial evaluating the use of KVD001 in patients with diabetic macular edema (DME).

Furthermore, adoption of inorganic growth strategies such as partnerships and collaborations, in order to develop innovative protease C1-inhibitor treatment is significantly contributing to the growth of global plasma protease C1-inhibitor treatment market. For instance, in October 2017, KalVista Pharmaceuticals, Inc. entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada for KVD001 (investigational plasma kallikrein inhibitors). The company’s investigational intravitreal (IVT) injection candidate is currently in development for potential treatment of diabetic macular edema (DME).

Plasma Protease C1-inhibitor Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2019	Market Size in 2020:	US$ 3,289.5 Mn
Historical Data for:	2016 to 2019	Forecast Period:	2020 to 2027
Forecast Period 2020 to 2027 CAGR:	18.2%	2027 Value Projection:	US$ 10,603.4 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC, Israel, and Rest of the Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Type: C1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist. By Dosage: Lyophilized, Injectable. By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:	CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.
Growth Drivers:	Increasing product approvals/ launches Increasing research and development Adoption of inorganic strategies
Restraints & Challenges:	The rare occurrence of the HAE Lower diagnosis rate

Global Plasma Protease C1-inhibitor Treatment Market - Restraints

However, the rare occurrence of the HAE makes it difficult for efficient diagnosis and opting alternative therapies to control the disease are the major factors that are expected to restrain the plasma protease c1-inhibitor treatment market growth over the forecast period.

Figure 2. Global Plasma Protease C1-inhibitor Treatment Market Share (%), by Region, 2020

Global Plasma Protease C1-inhibitor Treatment Market - Regional Analysis

On the basis of region, the global plasma protease C1-inhibitor treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America plasma protease C1-inhibitor treatment market is expected to exhibit significant growth during the forecast period, owing to increasing approvals of novel therapies by the regulatory agencies such as the U.S. Food and Drug Administration. For instance, in 2014, the U.S. FDA approved Pharming Healthcare’s Ruconest, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE.

Key Players:

Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.

Table of Content

*Browse 32 market data tables and 30 figures on " Plasma Protease C1-inhibitor Treatment Market – Global forecast to 2027”.

N/A

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2020-2027)?

The global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 3,289.5 million in 2020 and is expected to exhibit a CAGR of 18.2% between 2020 and 2027.

What are the major drivers driving the global plasma protease C1-inhibitor treatment market growth?

Increasing products approvals, rising research and development, adoption of inorganic growth strategies by key players are the factors that are driving growth of the global plasma protease C1-inhibitor treatment market.

Which is the leading drug type segment in the global plasma protease C1-inhibitor treatment market?

CI-inhibitors segment is estimated to account for major share in the plasma protease C1-inhibitor treatment market during the forecast period.

Which is the leading dosage segment in the global plasma protease C1-inhibitor treatment market?

Lyophilized segment is estimated to hold major market share in 2020, owing to increasing focus of pharmaceutical companies on development of lyophilized plasma protease C1-inhibitor.

Which region is estimated to generate the largest market share in 2020 in the global Plasma Protease C1-inhibitor Treatment Market?

North America is estimated to generate highest revenue share in 2020 in the global plasma protease C1-inhibitor treatment market during the forecast period.

Which are the key factors hampering growth of the market?

The rare occurrence of the HAE is expected to hamper growth of the global plasma protease C1-inhibitor treatment market during the forecast period.